Effect of Exenatide on ?? Cell Function After Islet Transplantation in Type 1 Diabetes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Islet transplantation can reduce or eliminate the need for insulin in patients with type 1 diabetes. Exenatide is a long acting analogue of Glucagon-like peptide-1 (GLP-1) that augments glucose induced insulin secretion, and may increase beta cell mass. We evaluated the effect of exenatide on insulin secretion after islet transplantation. METHODS: Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months. Response was assessed by insulin requirements, meal tolerance tests, and hyperglycemic glucose clamps. RESULTS: Ten patients responded to exenatide. Two patients who had not restarted insulin achieved good glycemic control and one patient who had received 5500 IE/kg in first islet infusion was able to stop insulin. Seven other patients decreased their insulin dose by 39% on exenatide. Hyperglycemic clamp studies showed a rise in second phase insulin release (before exenatide: 246+/-88 pM; during exenatide: 644+/-294 pM, P<0.01). Meal tolerance studies before and one month after stopping exenatide did not show a difference in glucose or C-peptide values. Nausea and vomiting were the major side effects. CONCLUSIONS: Exenatide stimulates insulin secretion in islet transplant recipients. It reduces insulin dose in some patients and may delay the need to resume insulin in others. We did not find any evidence of a trophic effect on islets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-Up After Clinical Islet Transplantation
Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R. T., & Shapiro, A. M. J. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2060 · Cited by 1,641
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 3×
“This has not been reported in patients with type 2 diabetes, although the studies do not appear to have been designed to look for this effect (6, 7).”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 3×
“This has not been reported in patients with type 2 diabetes, although the studies do not appear to have been designed to look for this effect (6, 7).”
BackgroundFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 1×
“Studies, including those using human islets (19), that show exenatide causing cell proliferation and/or decreased apoptosis have generally used concentrations of 10 nM with a duration of exenatide exposure of days to weeks (8).”
BackgroundSulfonylurea Stimulation of Insulin Secretion
Proks, P., Reimann, F., Green, N., Gribble, F., & Ashcroft, F. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s368 · Cited by 510
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Cited by
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions
Rickels, M. R., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00154 · Cited by 329
Update on Islet Transplantation
McCall, M., & James Shapiro, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007823 · Cited by 226
Bruin, J. E., Rezania, A., Xu, J., Narayan, K., Fox, J. K., O’Neil, J. J., & Kieffer, T. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2955-4 · Cited by 216
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166
“The use of exenatide therapy in patients with type 1 diabetes [16, 17], despite limited knowledge of the putative immunoregulatory role of the GLP-1R, prompted us to ascertain whether the GLP-1R is active in a range of immune cells.”
Background
Metadata
- Authors
- Ghofaili, K. A., Fung, M., Ao, Z., Meloche, M., Shapiro, R. J., Warnock, G. L., Elahi, D., Meneilly, G. S., & Thompson, D. M.
- Venue
- Transplantation
- Published
- 2007-01
- Volume
- 83
- Issue
- 1
- Pages
- 24-28
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2038327000
- Cited by
- 130
- References
- 6
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Exenatide on ?? Cell Function After Islet Transplantation in Type 1 Diabetes. https://app.cochat.ai/papers/10.1097/01.tp.0000251379.46596.2d
- The paper
- Ghofaili, K. A., Fung, M., Ao, Z., Meloche, M., Shapiro, R. J., Warnock, G. L., Elahi, D., Meneilly, G. S., & Thompson, D. M. (2007). Effect of Exenatide on ?? Cell Function After Islet Transplantation in Type 1 Diabetes. Transplantation. https://doi.org/10.1097/01.tp.0000251379.46596.2d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.